Science & Enterprise subscription

Follow us on Twitter

  • I just published Get Ready for Biological Programming, on Medium https://t.co/DGTKC7c4t0 Writing code with cells and genes.
    about 21 hours ago
  • The Pew Research Center last month reported results of surveys about mobile phone use, conducted in 11 emerging eco… https://t.co/EEmV2FmKas
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Mobile Phones in Emerging Economies https://t.co/MXoyQkhwIu #Science #Business
    about 2 days ago
  • Thank you @SciSeeker ... that's very kind. Where can I find a Science Seeker logo I can put on our site, to indicat… https://t.co/kXVMa32BHZ
    about 3 days ago
  • A biomedical engineering team devised techniques using a gel to produce more engineered T-cells, which in lab mice… https://t.co/d9GwEsAjxo
    about 3 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Protein Biotech Lands $51.5M in First Venture Round

Finance, calculator

(stevepb, Pixabay)

30 June 2016. A new spin-off biotechnology enterprise from Harvard University developing therapies that block signaling proteins causing disease, is raising $51.5 million its first venture funding round. This first-round financing for Morphic Therapeutic in Waltham, Massachusetts is led by the venture capital arms of pharmaceutical companies GlaxoSmithKline and Pfizer.

Morphic Therapeutic creates small molecule, or low molecular weight, treatments that block the activity of integrins, a class of proteins in humans and other animals that attach cell skeletons to the extracellular matrix, the network of molecules providing structural and biochemical support for cells. Integrins provide signaling pathways going into the cell from outside, and out of the cell from inside, acting as receptors for binding molecules affecting cell activities, as well as other proteins. Many biological processes function normally with integrins, but when integrins send aberrant signals, a number of diseases can result.

Timothy Springer, an immunologist and biophysicist at Harvard Medical School and Boston Children’s Hospital, has studied integrins since the 1980s. His lab’s research led to early treatments — administered with injections — already approved to address integrins associated with a number of diseases: multiple sclerosis, ulcerative colitis, Crohn’s disease, plaque psoriasis, acute coronary syndrome, and complications during procedures implanting a stent to open arteries.

Springer founded Morphic Therapeutic to bring to market more recent research with small molecule compounds that could lead to oral drugs rather than injections. The company says that technology licensed from Springer’s lab at Harvard is designed to overcome challenges that up to now prevented development of small-molecule oral drugs blocking signaling activity of integrin targets in diseased tissue. Morphic expects to design treatments for immunological diseases, fibrotic and vascular disorders, and neoplastic conditions, those causing abnormal growth of tissue from rapid or uncontrolled cell division.

The company’s first financing round is lead by SR One, the venture capital arm of GlaxoSmithKline and Pfizer Venture investments. Joining the round are AbbVie Ventures, another pharmaceutical venture group, as well as Omega Ventures. Polaris Partners, ShangPharma Investment Group, Schrödinger Inc., and Springer himself were original seed investors. The $51.5 million raised is expected to support research and development of multiple drug candidates into clinical trials.

Original investor Schrödinger Inc., a company making software for computational biology, is also collaborating with Morphic on design and discovery of small molecule drug candidates.

Read more:

Disclosure: The author owns shares in Pfizer.

*     *     *

Please share Science & Enterprise ...

1 comment to Protein Biotech Lands $51.5M in First Venture Round